REP-0003 / CDP for Atherosclerosis
Atherosclerosis / Cardiovascular Disease
Pre-clinicalActive
Key Facts
Indication
Atherosclerosis / Cardiovascular Disease
Phase
Pre-clinical
Status
Active
Company
About Repair Biotechnologies
Repair Biotechnologies is pioneering a first-in-class Cholesterol Degrading Platform (CDP) designed to treat diseases caused by localized cholesterol accumulation. Its most advanced application targets the reversal of atherosclerosis, with preclinical data showing significant plaque reduction. The company is privately held, in the pre-clinical stage, and has established a key manufacturing partnership with AGC Biologics to advance its mRNA-based therapeutic candidates.
View full company profile